Description

Vemurafenib-d7 is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].–Applications-Cancer-Kinase/protease-Formula-C23H11D7ClF2N3O3S-Citation–References-[1]Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.|[2]Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.|[3]Shelledy L, et al. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or MetastaticMelanoma. J Adv Pract Oncol. 2015 Jul-Aug;6(4):361-5.|[4]Wang W, et al. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.J Clin Endocrinol Metab. 2017 Feb 1;102(2):634-643.|[5]Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010, 70(13), 5518-5527.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber-1365986-73-7-MolecularWeight-496.97-Compound Purity–SMILES-O=C(C1=C(C(NS(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])(=O)=O)=CC=C1F)F)C2=CNC3=NC=C(C4=CC=C(C=C4)Cl)C=C23-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Autophagy;Isotope-Labeled Compounds;Raf-Isoform–Pathway-Autophagy;MAPK/ERK Pathway;Others-MCE Product type-Isotope-Labeled Compounds